75 results
8-K
EX-10.1
OCUL
Ocular Therapeutix Inc
22 Feb 24
Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement
7:34am
, there is no pending or threatened investigation that would reasonably be expected to lead to such a claim.
4.16. Legal Proceedings … contemplated hereby. Neither such inquiries nor any other due diligence investigation conducted by such Investor shall modify, limit or otherwise affect
8-K
EX-4.1
OCUL
Ocular Therapeutix Inc
22 Feb 24
Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement
7:34am
be reimbursed by the other party for their reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation
8-K
EX-1.1
OCUL
Ocular Therapeutix Inc
14 Dec 23
Ocular TherapeutixTM Announces Pricing of Public Offering of Common Stock
8:46am
investigation, remediation, or other corrective action pursuant to any Privacy Law; or (iii) is a party to any order, decree, or agreement that imposes any … ; (iv) has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the FDA
8-K
EX-1.1
1h6 y0nt6b508
9 Aug 21
Entry into a Material Definitive Agreement
4:48pm
8-K
EX-10.1
195z22
4 Jun 21
Entry into a Material Definitive Agreement
4:34pm
8-K
EX-1.1
twjq9i e1joqqt
18 Dec 20
Ocular Therapeutix™ Announces Proposed Public Offering of Common Stock
6:30am